1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Switzerland >
  5. Abiogen Pharma Acquires EffRx

M&A Deal Summary

Abiogen Pharma Acquires EffRx

On May 29, 2023, Abiogen Pharma acquired life science company EffRx

Acquisition Highlights
  • This is Abiogen Pharma’s 1st transaction in the Life Science sector.
  • This is Abiogen Pharma’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2023-05-29
Target EffRx
Sector Life Science
Buyer(s) Abiogen Pharma
Deal Type Add-on Acquisition

Target

EffRx

Freienbach, Switzerland
EffRx develops and commercializes drugs, targeted in particular to musculoskeletal and rare diseases. The company's product range includes buffered soluble alendronate, a key agent from the class of bisphosphonates used in the treatment of osteoporosis. It licenses and distributes this drug under license agreements in 29 European and non-European countries. EffRx was founded in 2010 and is based in Freienbach, Switzerland.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Abiogen Pharma

Pisa, Italy
Category Company
Founded 1997
Sector Life Science
DESCRIPTION

Abiogen Pharma research and development, manufacturing of pharmaceuticals with its own brand or under third-party contracts, and marketing of own and licensed drugs. Abiogen Pharma was founded in 1997 and is based in Pisa, Italy.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Switzerland M&A 1 of 1
Year: 2023 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-08 Altamedics

Koln, Germany

Altamedics distributes pharmaceuticals – namely hospital products – on the domestic and on several international markets, via third-party manufacturing sites and its warehouse and logistics centre in Neunkirchen. Altamedics was founded in 2009 and is based in Koln, Germany.

Buy -
Mergr

Solution for

Product

Company

Legal